ARUP's Laboratory Test Directory
| 0051186: Human Immunodeficiency Virus 1, virco®TYPE |
| Test Mnemonic: HIV1VT | |
|
Methodology: Reverse Transcription Polymerase Chain Reaction and DNA Sequencing with interpretation using a phenotypic database
Performed: Tue-Sat Reported: 6-10 days |
| Specimen Required: | |
|
Collect: Two 5 mL lavender (EDTA) or pink (K2EDTA), or two beige (PPT). Remove EDTA plasma from cells ASAP. Centrifuge PPT plasma ASAP.
Transport: 5 mL plasma (EDTA or beige, PPT), frozen. (Min: 2.5 mL) Submit specimen in an ARUP Standard Transport Tube. Submit specimen according to Biological Substance, Category B, shipping guidelines. Pediatric Collection/Transport: 2.5 mL plasma (EDTA or beige, PPT), frozen. Submit specimen according to Biological Substance, Category B, shipping guidelines. Remarks: CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered. Remove EDTA plasma from cells ASAP and freeze in a polypropylene tube at -20°C for transport. Spin PPT ASAP and freeze at -20°C or lower for transport. This test may be unsuccessful if the plasma HIV-1 RNA viral load is less than 1,000 HIV-1 RNA copies per mL of plasma. Unacceptable Conditions: Serum or whole blood. Heparinized or nonfrozen specimens. Specimens exposed to repeated freeze/thaw cycles. Stability: After separation from cells: Ambient: 30 minutes; Refrigerated: 2 hours; Frozen: 4 months |
|
| Reference Interval: |
| By report |
| Interpretive Data: | |
|
The virco®TYPE HIV-1 assay is a system for predicting HIV-1 drug resistance from the nucleic acid sequence of the human immunodeficiency virus. The virco®TYPE HIV-1 analysis is based on sequences encompassing the entire protease gene (codons 1-99) and codons 1-400 of the reverse transcriptase, covering the essential resistance-associated mutations. Virus from the patient is sequenced at ARUP Laboratories and the sequence is sent to Virco for analysis. Sequence data is obtained for codons 1-99 of the protease gene and codons 1-335 of the reverse transcriptase gene. Sample sequence data undergoes VirtualPhenotype Linear Modeling analysis (www.vircolab.com) and a virco®TYPE report is generated. A patient's response to therapy depends on multiple factors, including the percentage of a patient's viral population that is resistant, patient compliance, access to adequate care, optimal dosing, and drug pharmacology issues, including absorption, elimination, and drug interactions. Therefore, this test should be used only in conjunction with clinical expertise and other laboratory markers (e.g., symptoms, treatment history, clinical impression, results from other tests, etc.) when making therapeutic decisions. Results from different test methods may provide different resistance interpretations. This test may be unsuccessful if the plasma HIV-1 RNA viral load is less than 1,000 HIV-1 copies of virus per mL of plasma, as measured with the Roche Amplicor Monitor assay (Roche Diagnostic Systems, Branchburg, NJ). This test may not detect minor HIV-1 populations resistant to drugs that are not being administered to the patient. The ARUP HIV-1 Genotyping Assay uses the Viroseq™ HIV-1 Genotyping System Software to identify mutations associated with drug resistance. According to the Viroseq™ software manual, some insertions/deletions may be difficult to detect using this software; therefore, in rare cases, insertions/deletions in the viral sequence may result in an inaccurate drug resistance report. The performance characteristics of this test were determined by ARUP Laboratories, Inc. |
| Note: | |
| For a complete list of drugs currently profiled by this assay, please contact ARUP Client Services. |
| CPT Code(s): | |
| 87900 Phenotype prediction using genotypic bioinformatics; 87901 Genotype analysis by nucleic acid |